Carl Zeiss X-Ray Microscopy vs. Sigray: X-Ray Imaging Patent Verdict
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Carl Zeiss X-Ray Microscopy, Inc. v. Sigray, Inc. |
| Case Number | 5:21-cv-01129 (N.D. Cal.) |
| Court | U.S. District Court, Northern District of California |
| Duration | Feb 2021 – Jan 2026 4 years 11 months |
| Outcome | Plaintiff Win — $785K Damages |
| Patents at Issue | |
| Accused Products | Sigray TriLambda NanoXRM Microscope, Prisma, Eclipse |
Case Overview
The Parties
⚖️ Plaintiff
X-ray microscopy division of the globally recognized Carl Zeiss group, a leader in optical and imaging systems with a significant patent portfolio in x-ray optics and nano-scale imaging.
🛡️ Defendant
California-based startup specializing in advanced x-ray technology, including laboratory-scale x-ray sources and microscopy systems competing in the nano-resolution imaging market.
The Patents at Issue
This landmark case involved two U.S. patents protecting foundational x-ray microscopy apparatus and detection technology, critical to high-resolution imaging in semiconductor inspection, materials science, and life sciences research.
- • U.S. Patent No. 7,057,187 — covering x-ray microscopy apparatus and detection technology. Key claims 1–6, 8–12, and 17 were found infringed.
- • U.S. Patent No. 7,400,704 — directed to x-ray imaging systems and optical configurations. Key claims 7, 9–15 were found infringed.
Developing a similar x-ray imaging product?
Check if your product design might infringe these or related patents before launch.
The Verdict & Legal Analysis
Outcome Summary
The jury delivered a split verdict, finding Sigray liable for infringing Carl Zeiss’s x-ray microscopy patents and awarding $785,000 in damages as a reasonable royalty. This outcome highlights the significant value of legacy patent portfolios in specialized technology markets.
Patent Damages Awarded
| Product | Patent(s) | Damages |
|---|---|---|
| TriLambda | ‘187 Patent | $170,000 |
| Prisma | ‘187 & ‘704 Patents | $421,000 |
| Eclipse | ‘704 Patent | $194,000 |
| Total | $785,000 |
Key Legal Issues
All infringement findings rested on literal infringement, establishing that Sigray’s accused products embodied each element of the asserted claims without relying on the doctrine of equivalents. This is a robust finding for the plaintiff, reinforcing clear claim scope.
Critically, the jury found Sigray’s infringement was not willful, protecting Sigray from potentially triple damages under 35 U.S.C. § 284. This demonstrates the effectiveness of a strong defense against willfulness, likely by presenting reasonable beliefs in non-infringement or invalidity.
Parallel trade secret claims resulted in a **partial defense victory** for Sigray. While some alleged trade secrets were found to qualify as such, the jury found no misappropriation of any of the 15 alleged trade secrets. This underscores the high evidentiary bar for proving both the existence of a trade secret and its improper use.
Freedom to Operate (FTO) Analysis in X-Ray Imaging
This case highlights critical IP risks in the scientific instrumentation and x-ray microscopy market. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation.
- View all related patents in this technology space
- See which companies are most active in x-ray imaging patents
- Understand claim construction patterns for optical systems
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own technology or product.
- Input your product description or technical features
- AI identifies potentially blocking patents in x-ray optics
- Get actionable risk assessment report
High Risk Area
Precision X-ray microscopy apparatus
2 Patents Infringed
Foundational x-ray optical systems
No Willful Infringement
Avoided enhanced damages
✅ Key Takeaways
Literal infringement findings across multiple claims and products significantly strengthen a plaintiff’s position.
Search related case law →A successful defense against willfulness can protect defendants from enhanced damages, emphasizing the importance of building a contemporaneous good-faith record.
Explore precedents →Trade secret claims, while adding complexity, require meeting distinct evidentiary standards for both existence and misappropriation.
Learn more about trade secret litigation →Multi-patent, multi-product assertion strategies maximize royalty exposure and negotiating leverage in specialized technology markets.
Analyze patent portfolio strategy →Reasonable royalty damages in niche instrumentation markets provide useful licensing benchmarks for future negotiations or expert damages analyses.
Benchmark licensing rates →Frequently Asked Questions
The case involved U.S. Patent No. 7,057,187 and U.S. Patent No. 7,400,704, both directed to x-ray microscopy imaging systems and optical configurations.
The jury awarded $785,000 in total reasonable royalties across three accused Sigray products: TriLambda ($170,000), Prisma ($421,000), and Eclipse ($194,000).
The jury found no misappropriation of any alleged trade secrets — meaning even those qualifying as trade secrets were not improperly acquired or used by Sigray, defeating the claim on its merits.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- PACER — Case No. 5:21-cv-01129, U.S. District Court, Northern District of California
- USPTO Patent Center — U.S. Patent No. 7,057,187
- USPTO Patent Center — U.S. Patent No. 7,400,704
- Cornell Legal Information Institute — 35 U.S.C. § 284 (Damages)
- PatSnap — IP Intelligence Solutions for Law Firms
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.